Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1999-06-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.96.12.7053PMID 10359837PMCID PMC22053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A good antisense molecule is hard to find

  1998cited by this paper
• Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo

  1998cited by this paper
• In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine, antagonize neurotensin-mediated antinociception.

  1998cited by this paper
• A good antisense molecule is hard to find.

  1998cited by this paper
• Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo

  1998cited by this paper
• Peptide nucleic acids: expanding the scope of nucleic acid recognition.

  1997cited by this paper
• Efficient in vitro inhibition of HIV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA.

  1997cited by this paper
• Presence and characterization of nociceptin (orphanin FQ) receptor binding in adult rat and human fetal hypothalamus.

  1997cited by this paper
• In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA).

  1997cited by this paper
• Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.

  1996cited by this paper
• Antisense properties of duplex- and triplex-forming PNAs.

  1996cited by this paper
• Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

  1996cited by this paper
• Structure, Functional Expression, and Cerebral Localization of the Levocabastine-Sensitive Neurotensin/Neuromedin N Receptor from Mouse Brain

  1996cited by this paper
• Molecular cloning of a levocabastine‐sensitive neurotensin binding site

  1996cited by this paper
• Phospholipid membrane permeability of peptide nucleic acid

  1995cited by this paper
• Phospholipid membrane permeability of peptide nucleic acid.

  1995cited by this paper
• Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo.

  1995cited by this paper
• Mechanism of Lac repressor switch‐off: orientation of the Lac repressor DNA‐binding domain is reversed upon inducer binding

  1995cited by this paper
• Stability of peptide nucleic acids in human serum and cellular extracts.

  1994cited by this paper
• Peptide nucleic acid.DNA strand displacement loops as artificial transcription promoters.

  1994cited by this paper
• Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.

  1993cited by this paper
• Identification of a polymorphism in the human neurotensin receptor gene.

  1993cited by this paper
• Peptide nucleic acids (PNAs): potential antisense and anti-gene agents.

  1993cited by this paper
• Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor

  1993cited by this paper
• Antisense and antigene properties of peptide nucleic acids.

  1992cited by this paper
• Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem.

  1991cited by this paper
• Structure and functional expression of the cloned rat neurotensin receptor.

  1990cited by this paper
• Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution.

  1984cited by this paper
• Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin

  1976cited by this paper
• The amino acid sequence of a hypothalamic peptide, neurotensin.

  1975cited by this paper

• Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptides

  2025cites this paper
• Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002

  2024cites this paper
• Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.

  2023cites this paper
• The Blood–Brain Barrier and CNS Drug Delivery

  2021cites this paper
• Explorations into Peptide Nucleic Acid Contrast Agents as Emerging Scaffolds for Breakthrough Solutions in Medical Imaging and Diagnosis

  2021cites this paper
• Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood–brain barrier and knock down genes in the rodent CNS

  2021cites this paper
• Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog.

  2021cites this paper
• A liquid biopsy platform for detecting gene-gene fusions as glioma diagnostic biomarkers and drug targets

  2020cites this paper
• Effect of peptidic backbone on the nucleic acid dimeric strands

  2020cites this paper
• Oligonucleotide Synthesis

  2020cites this paper
• Recent Advances in Peptide Nucleic Acids as Antibacterial Agents.

  2020cites this paper
• Background and Analysis of Nucleic Acids

  2019cites this paper
• A Review of MicroRNA Biomarkers in Traumatic Brain Injury

  2019cites this paper
• Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates

  2018cites this paper
• Medicinal chemistry approaches for novel DNA ligands

  2018cites this paper
• Caractérisation fonctionnelle du récepteur de type 2 de la neurotensine dans la résistance à la mort cellulaire des lymphocytes B au cours de la Leucémie Lymphoïde Chronique

  2017cites this paper
• Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities

  2017cites this paper
• 
Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities


  2017cites this paper
• Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

  2016cites this paper
• Conformational studies of chiral D-Lys-PNA and achiral PNA system in binding with DNA or RNA through a molecular dynamics approach.

  2015cites this paper
• « Les PNA : une décennie après, quels espoirs ? / One decade later, what future for PNA ? »

  2015cites this paper
• Other Body Fluids as Non-invasive Sources of Cell-Free DNA/RNA

  2015cites this paper
• Molecular properties and medical applications of peptide nucleic acids.

  2014cites this paper
• Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics

  2014cites this paper
• Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon

  2014cites this paper
• PNA as a potential modulator of COL7A1 gene expression in dominant dystrophic epidermolysis bullosa: a physico-chemical study.

  2013cites this paper
• Inhibition of Human Immunodeficiency Virus Replication by Cell Membrane-Crossing Oligomers

  2012cites this paper
• Growth Factor- and Adhesion Protein-Like Components of Fetal Calf Serum Can Significantly Enhance the Intracellular Delivery of Peptide Nucleic Acids

  2011cites this paper
• Evidence for extensive non-endocytotic translocation of peptide nucleic acids across mammalian plasma membranes.

  2011cites this paper
• Gene Therapy in Heart Failure: Forthcoming Therapies

  2010cites this paper
• Involvement of NTS2 receptors in stress-induced analgesia.

  2010cites this paper
• Altered morphine-induced analgesia in neurotensin type 1 receptor null mice.

  2010cites this paper
• Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.

  2009cites this paper
• Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides

  2009cites this paper
• Synthesis, Spectroscopic Properties and Electrochemical Oxidation of RuII‐Polypyridyl Complexes Attached to a Peptide Nucleic Acid Monomer Backbone

  2009cites this paper
• Inhibition of Japanese encephalitis virus replication by peptide nucleic acids targeting cis-acting elements on the plus- and minus-strands of viral RNA.

  2009cites this paper
• Isolation of Peptide Transport System-6 from Brain Endothelial Cells: Therapeutic Effects with Antisense Inhibition in Alzheimer and Stroke Models

  2009cites this paper
• Characteristics of compounds that cross the blood-brain barrier

  2009cites this paper
• Synthesis of potential cell-penetrating peptide nucleic acid conjugates

  2008cites this paper
• Inibizione selettiva del gene MYCN mediante PNA (acidi peptido nucleici) anti-gene nel rabdomiosarcoma umano

  2008cites this paper
• Peptide nucleic acids: on the road to new gene therapeutic drugs.

  2008cites this paper
• Blocking the CC chemokine receptor 5 pathway by antisense peptide nucleic acid prolongs islet allograft survival.

  2007cites this paper
• Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA.

  2007cites this paper
• CHAPTER 3 – Cardiovascular Gene Expression

  2007cites this paper
• Down-regulation of amyloid precursor protein by peptide nucleic acid in vivo

  2007cites this paper
• Radiolabelled Oligonucleotides for Evaluation of in vivo Hybridisation Utilising PET Methodology

  2007cites this paper
• Peptide nucleic acids targeted to the amyloid precursor protein

  2007cites this paper
• Neurotensin and pain modulation.

  2006cites this paper
• Functional roles of the NTS2 and NTS3 receptors.

  2006cites this paper
• Preproenkephalin targeted antisenses cross the blood-brain barrier to reduce brain methionine enkephalin levels and increase voluntary ethanol drinking.

  2006cites this paper
• Biological activity and biotechnological aspects of peptide nucleic acid.

  2006cites this paper
• RNA targeting using peptide nucleic acid.

  2006cites this paper
• Inflammatory cytokines and NFκB in Alzheimer’s disease.

  2006cites this paper
• Anti-gene peptide nucleic acid targeted to proviral HIV-1 DNA inhibits in vitro HIV-1 replication.

  2005cites this paper
• Transport of antisense across the blood-brain barrier.

  2005cites this paper
• PNA-Ligand Bioconjugates as Potential Building Blocks for Sequence-Specific, Metal-Mediated DNA-/RNA-Cleavage

  2005cites this paper
• Multitasking with neurotensin in the central nervous system

  2005cites this paper
• From CENTER FOR GENOMICS AND BIOINFORMATICS Karolinska Institutet, Stockholm, Sweden BACTERIAL GENE EXPRESSION INHIBITION WITH ANTISENSE PEPTIDE NUCLEIC ACIDS

  2005cites this paper
• Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment.

  2005cites this paper
• Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide.

  2005cites this paper
• Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases.

  2005cites this paper
• [The peptide nucleic acids (PNAs): "high-tech" probes for genetic and molecular cytogenetic investigations].

  2005cites this paper
• Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain.

  2005cites this paper
• Pharmacologically selective block of mu opioid antinociception by peptide nucleic acid antisense in absence of detectable ex vivo knockdown.

  2005cites this paper
• Review Multitasking with neurotensin in the central nervous system

  2005cites this paper
• Les PNA (peptide nucleic acids) : Des sondes high-tech pour l’analyse génétique et cytogénétique moléculaire

  2005cites this paper
• BACTERIAL GENE EXPRESSION INHIBITION WITH ANTISENSE PEPTIDE NUCLEIC ACIDS

  2005cites this paper
• Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis

  2005cites this paper
• PNA technology

  2004cites this paper
• [One decade later, what future for PNA?].

  2004cites this paper
• Antisense therapeutics and the treatment of CNS disease.

  2004cites this paper
• Cell-free fetal DNA in the cerebrospinal fluid of women during the peripartum period.

  2004cites this paper
• Low-Affinity Neurotensin Receptor (NTS2) Signaling: Internalization-Dependent Activation of Extracellular Signal-Regulated Kinases 1/2

  2004influential citation
• Mechanisms of Antisense Transport across the Blood–Brain Barrier

  2004cites this paper
• Identification and functional characterization of novel receptor ligands of CD40 and alpha(v) beta(3) integrin: implications for gene delivery

  2004cites this paper
• Identification and analysis of the minimal promoter activity of a novel noncoding nuclear RNA gene, AncR-1, from the honeybee (Apis mellifera L.).

  2004cites this paper
• Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro.

  2004cites this paper
• Low-affinity neurotensin receptor (NTS2) signaling: Internalization-dependent activation of ERK1/2

  2004cites this paper
• Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression

  2004cites this paper
• PNA ( peptide nucleic acid ) anti-gene / antisense can access intact viable cells and downregulate target genes

  2004cites this paper
• Antiaging methods and medicines for the memory.

  2004cites this paper
• Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.

  2004influential citation
• Les PNA : une décennie après, quels espoirs ?

  2004cites this paper
• Recent advances in the development of peptide nucleic acid as a gene-targeted drug

  2004cites this paper
• Anti-gene strategies to down-regulate gene expression in mammalian cells.

  2004cites this paper
• Recognition of chromosomal DNA by PNAs.

  2004cites this paper
• Peptide nucleic acid (PNA) binding-mediated gene regulation

  2004cites this paper
• Peptide nucleic acids as agents to modify target gene expression and function

  2003cites this paper
• Peptide nucleic acids as epigenetic inhibitors of HIV-1

  2003cites this paper
• Antisense peptide nucleic acid‐mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice

  2003cites this paper
• Putting some spine into alternative splicing.

  2003cites this paper
• The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia.

  2003cites this paper
• Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes.

  2003cites this paper
• A targeted peptide nucleic acid to down-regulate mouse microsomal triglyceride transfer protein expression in hepatocytes.

  2003cites this paper
• PNAs as novel cancer therapeutics

  2003cites this paper
• Correction of disease-associated exon skipping by synthetic exon-specific activators

  2003cites this paper
• The potential of antisense as a CNS therapeutic

  2003cites this paper
• Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers.

  2003cites this paper
• Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.

  2003cites this paper
• Blockade of plasmid replication mediated by peptide nucleic acids

  2003cites this paper